The company is currently developing emricasan, an orally active pan-caspase inhibitor, for the treatment of chronic liver disease. They are also working on CTS-2090, a selective caspase inhibitor for diseases involving inflammasome pathways. Conatus Pharmaceuticals' lead program, CTS-1027, is in Phase 2 clinical trials for treating Hepatitis C Virus. The company's goal is to develop therapeutics to treat liver disease and cancer.